Ignite Creation Date:
2024-05-05 @ 4:55 PM
Last Modification Date:
2024-10-26 @ 9:25 AM
Study NCT ID:
NCT00343720
Status:
COMPLETED
Last Update Posted:
2008-03-13
First Post:
2006-06-22
Brief Title:
Study of Alimta Pemetrexed Plus VELCADE Bortezomib or Alimta Alone or VELCADE Alone in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Prior Therapy
Sponsor:
Millennium Pharmaceuticals Inc
Organization:
Millennium Pharmaceuticals Inc
Study Overview
Official Title:
A Randomized Open-Label Multicenter Study of Alimta Pemetrexed Plus VELCADE Bortezomib or Alimta Alone or VELCADE Alone in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Prior Antineoplastic Therapy
Status:
COMPLETED
Status Verified Date:
2008-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to establish the objective response rate complete response partial response following treatment with Alimta plus VELCADE Alimta alone or VELCADE alone in patients with locally advanced or metastatic non-small cell lung cancer NSCLC who have failed prior preventative therapy for Stage IIIbIV NSCLC The Alimta alone treatment group will be used as the control The VELCADE single-agent treatment group will be used to determine if VELCADE administered weekly can demonstrate response rates
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None